Financial Performance - As of September 30, 2025, the accumulated deficit was $(109.5) million, with net losses before income tax of $6.0 million and $18.6 million for the three months and nine months ended September 30, 2025, respectively[72]. - The company does not expect to generate any revenue in 2025 and anticipates significant and increasing operating losses in the foreseeable future[72]. - The company expects to continue incurring operating losses in the future, with no anticipated additional revenue from the clinical manufacturing agreement with Janssen[100]. Research and Development Expenses - Research and development expenses totaled $5.1 million and $22.0 million for the three months and nine months ended September 30, 2025, representing decreases of 29% and 26% compared to the same periods in 2024[89][90]. - Clinical trials and sponsored research expenses dropped significantly, with no active trials during the three months and nine months ended September 30, 2025, leading to an 88% decrease in related costs[90]. - Share-based compensation related to research and development accounted for $2.7 million for the nine months ended September 30, 2025, compared to $0.7 million for the same period in 2024, marking a 266% increase[90]. - Total research and development expenses from inception through September 30, 2025, reached $371.7 million[75]. General and Administrative Expenses - General and administrative expenses increased to $1.0 million for the three months ended September 30, 2025, up 24% from $0.8 million in the same period of 2024[91]. - General and administrative expenses as a percentage of total operating expenses were 16% and 15% for the three months and nine months ended September 30, 2025, compared to 10% and 11% for the same periods in 2024[80]. Cash Flow and Liquidity - Cash and cash equivalents as of September 30, 2025, totaled $147.4 million, down from $183.1 million at the same date in 2024, representing a decrease of about 19.5%[96]. - Net cash used in operating activities for the nine months ended September 30, 2025, was $16.968 million, an improvement from $24.423 million in 2024, indicating a reduction of approximately 30.2%[97]. - Net cash used in investing activities for the nine months ended September 30, 2025, was $255 thousand, significantly lower than $1.2 million in 2024, showing a decrease of about 78.8%[98]. - The effect of foreign exchange rates on cash and cash equivalents resulted in a gain of $2.163 million for the nine months ended September 30, 2025, compared to a loss of $1.429 million in 2024[96]. Other Income and Interest - Interest income for the three months ended September 30, 2025, was $1.427 million, a decrease from $2.369 million in 2024[94]. - Total other income for the nine months ended September 30, 2025, was $7.441 million, compared to $5.709 million in 2024, reflecting a year-over-year increase of approximately 30.4%[94]. Employment and Company Structure - The company had 88 employees as of September 30, 2025[72]. - The company has not engaged in any off-balance sheet activities since inception, including structured finance or special purpose entities[101]. - The company is not currently exposed to material market risks from financial instruments or fluctuations in foreign currencies, and does not engage in hedging activities[102]. Financing Activities - The Convertible Loan Agreement provided $10 million in net cash for the construction of a new research and development facility, which was fully repaid by January 31, 2025[99].

Financial Performance - As of June 30, 2025, the accumulated deficit was $103.5 million, with net losses of $1.8 million and $12.6 million for the three and six months ended June 30, 2025, respectively, compared to $13.0 million and $23.0 million for the same periods in 2024[71]. - The company does not expect to generate any revenue in 2025 and anticipates significant and increasing operating losses as drug candidates progress through development stages[71]. - The company expects to continue incurring operating losses in the future and does not anticipate additional revenue from the clinical manufacturing agreement with Janssen[96]. Research and Development Expenses - Total research and development expenses for the three months ended June 30, 2025 were $5.3 million, a decrease of $7.6 million (59%) from $13.0 million in the same period of 2024[86]. - Research and development expenses for the six months ended June 30, 2025 were $17.0 million, down $5.9 million (26%) from $22.8 million for the same period in 2024[87]. - Research and development expenses accounted for 84% and 85% of total operating expenses for the three and six months ended June 30, 2025, respectively, compared to 87% and 89% for the same periods in 2024[75]. - Share-based compensation related to research and development for the three months ended June 30, 2025 was $19 thousand, down 92% from $242 thousand in the same period of 2024[86]. - The total research and development expenses from inception through June 30, 2025 amounted to $366.6 million[74]. General and Administrative Expenses - General and administrative expenses for the three months ended June 30, 2025 were $1.0 million, a decrease of $982 thousand (50%) from $2.0 million in the same period of 2024[88]. - General and administrative expenses for the six months ended June 30, 2025 were $2.9 million, a slight decrease of $78 thousand (3%) from $3.0 million for the same period in 2024[88]. Cash Flow and Financial Position - Cash and cash equivalents as of June 30, 2025, totaled $152.9 million, down from $188.5 million at June 30, 2024, representing a decrease of about 19%[93]. - Net cash used in operating activities for the six months ended June 30, 2025, was $12.7 million, a reduction from $18.6 million in the same period of 2024, indicating a decrease of approximately 32%[93]. - Net cash used in investing activities was $145 thousand for the six months ended June 30, 2025, compared to $882 thousand in 2024, showing a decrease of about 84%[94]. - The Convertible Loan Agreement provided $10 million net cash for the construction of a new research and development facility, which was fully repaid by January 31, 2025[95]. - The company has funded operations through private placements and public offerings, raising approximately $276.3 million since inception[93]. Employee and Market Risk Information - The company had 92 employees as of June 30, 2025[71]. - The company has not engaged in any off-balance sheet activities since inception[97]. - The company is not currently exposed to material market risks from financial instruments or fluctuations in foreign currencies[98]. Interest Income and Foreign Exchange - Interest income for the three months ended June 30, 2025, was $1,530 thousand, compared to $2,689 thousand for the same period in 2024, reflecting a decrease of approximately 43%[91]. - Foreign exchange gains for the six months ended June 30, 2025, were $3,365 thousand, compared to a loss of $2,136 thousand in 2024, indicating a significant positive shift[91].

Financial Performance - As of March 31, 2025, XBiotech reported an accumulated deficit of $101.7 million and net losses of $10.9 million for the three months ended March 31, 2025, compared to $10.0 million for the same period in 2024[74]. - The company does not expect to generate any revenue in 2025 and anticipates significant operating losses as it advances its drug candidates[74]. - The company expects to continue incurring operating losses in the future[99]. - The company may not receive any product revenue until a drug candidate is approved by regulatory agencies[99]. Research and Development Expenses - Total research and development expenses for the three months ended March 31, 2025, were $11.6 million, an increase of 18% from $9.8 million in the same period of 2024[90]. - Salaries and related expenses within research and development increased by 56% to $6.4 million for the three months ended March 31, 2025, primarily due to a $4.0 million bonus to the CEO[89]. - Research and development expenses accounted for 86% of total operating expenses for the three months ended March 31, 2025, down from 91% in the same period of 2024[78]. - Stock-based compensation in research and development increased to $2.7 million for the three months ended March 31, 2025, compared to $255 thousand in the same period of 2024[90]. - The company has recorded total research and development expenses of $361.3 million from inception through March 31, 2025[77]. General and Administrative Expenses - General and administrative expenses rose to $1.9 million for the three months ended March 31, 2025, an increase of 88% from $1.0 million in the same period of 2024[92]. Cash and Cash Equivalents - The company had cash and cash equivalents of $155.9 million as of March 31, 2025, down from $201.0 million at March 31, 2024[95]. - As of March 31, 2025, the company's cash and cash equivalents totaled approximately $155.9 million[99]. Operating Activities - Operating activities used net cash of $6.7 million for the three months ended March 31, 2025, compared to $7.2 million in the same period of 2024[96]. Off-Balance Sheet Activities - The company has not engaged in any off-balance sheet activities since inception[100].

Financial Performance - XBiotech generated a total of $750 million in income from the sale of its True Human™ antibody Bermekimab between December 30, 2019, and June 30, 2021[28]. - The company returned a total of $495 million to shareholders through stock repurchase and dividends since 2020[28]. - The company has incurred significant losses since its inception and may continue to do so, with a net loss reported for the fiscal year ended December 31, 2024[52]. - The company has not generated any revenue from product sales to date and may never sustain profitability[58]. - The net loss for the year ended December 31, 2024, was $38,531,000, compared to a net loss of $24,557,000 in 2023, representing a 56.6% increase in losses[221]. - The accumulated deficit increased to $90.837 million as of December 31, 2024, compared to $52.306 million in 2023[209]. - The company does not expect to generate any revenue during the fiscal year of 2025 and anticipates significant and increasing operating losses as it advances drug candidates through testing[159]. Research and Development - XBiotech is developing two anti-IL-1a product candidates in parallel, targeting oncology, rheumatology, and neurology[27]. - A clinical study for Natrunix™ in pancreatic cancer included 60 subjects, showing reduced hospitalization and fewer serious adverse events compared to placebo[32]. - A clinical study for Natrunix in rheumatoid arthritis was completed with 233 subjects, but data was rendered uninterpretable due to enrollment irregularities[33]. - XBiotech completed a Phase I study for its True Human™ antibody Hutrukin, demonstrating safety and tolerability for stroke treatment[34]. - Research and development expenses for the year ended December 31, 2024, amounted to approximately $37.8 million[54]. - Total research and development expenses accounted for 89% of total operating expenses in 2024, up from 88% in 2023[165]. - The company recorded total research and development expenses of $349.7 million from inception through December 31, 2024[164]. - Clinical trial costs increased due to a new study initiated in the second quarter of 2023, contributing to the overall rise in research and development expenses[181]. Regulatory and Market Challenges - The company anticipates significant expenses will continue as it seeks regulatory approvals for current and future product candidates[53]. - The ability to generate revenue from product sales will depend on successful commercialization of product candidates, which have not yet received regulatory approval[62]. - The FDA review process for regulatory approval typically takes years and is not guaranteed[62]. - The regulatory approval process for product candidates is lengthy and unpredictable, typically taking several years and dependent on various factors[70]. - The FDA may require additional preclinical or clinical data, which could delay or prevent approval and commercialization plans[71]. - Clinical trials may fail to demonstrate safety and efficacy, or may not meet the statistical significance required for approval[72]. - Even with regulatory approval, products may face ongoing oversight and marketing challenges, including potential label restrictions[77]. - Coverage and adequate reimbursement from third-party payers are critical for successful commercialization, and there may be significant delays in obtaining these[87]. - The approval process in foreign jurisdictions may involve additional testing and could significantly delay product introduction[85]. - Changes in government regulations could prevent or delay regulatory approval of product candidates[84]. - The company may face litigation or product liability claims if adverse effects are identified post-approval[79]. - The occurrence of regulatory penalties could inhibit the ability to commercialize product candidates and generate revenue[81]. Competition and Market Position - The company faces substantial competition, which may hinder its ability to achieve market acceptance for its products[52]. - The company faces substantial competition from larger pharmaceutical and biotechnology companies, which may limit its ability to develop or commercialize product candidates[94]. - The success of the company's product candidates depends on market acceptance among physicians, patients, and healthcare payers, which is not guaranteed[91]. Financial Position and Capital Needs - The company may require substantial additional capital to continue clinical development and potential commercialization activities[55]. - The company funded operations through equity securities, raising approximately $118.2 million since inception, with significant cash proceeds from the Janssen Transaction[188]. - Cash and cash equivalents decreased to $172.7 million at December 31, 2024, down from $200.0 million at December 31, 2023[188]. - Net cash used in operating activities for the year ended December 31, 2024, was $31.0 million, an increase from $18.7 million in 2023, primarily due to net losses and increased expenses[189]. - The total assets decreased to $199.093 million in 2024 from $226.615 million in 2023, indicating a decline in financial position[209]. Management and Personnel - As of December 31, 2024, XBiotech had 92 full-time employees, with no collective bargaining agreements in place[43]. - The company is highly dependent on key personnel, including its Chief Executive Officer, for its operations[52]. - The company is dependent on its Chief Executive Officer, John Simard, whose loss could negatively impact the company's strategic direction[107]. - The company may struggle to attract and retain qualified personnel, which is critical for its research, development, and commercialization efforts[108]. Intellectual Property and Legal Risks - The company relies on patent protection for its proprietary technology, and the uncertainty surrounding patent issuance and enforcement could adversely affect its competitive position[116]. - The company may face challenges in protecting its intellectual property rights, which could allow competitors to develop similar technologies and products[117]. - The company faces risks related to potential infringement claims from third parties, which could result in costly litigation and diversion of resources[120]. Corporate Governance and Structure - The company has significant control over its common stock, with directors and principal shareholders owning approximately 44.2% of outstanding shares, potentially affecting corporate governance and market price[127]. - XBiotech is governed by the corporate laws in British Columbia, Canada, which may differ materially from those in Delaware, affecting shareholder rights[134].

Core Viewpoint - Pomerantz LLP is investigating claims on behalf of investors of XBiotech Inc. regarding potential securities fraud or unlawful business practices by the company and its officers [1][2]. Group 1: Company Developments - On December 23, 2024, XBiotech announced a pause in its phase 2 rheumatoid arthritis program after its candidate, Natrunix, failed to meet its primary endpoint, citing "substantial irregularities" that complicate the interpretation of findings [2]. - Following the announcement, XBiotech's stock price experienced a significant decline during intraday trading on the same day [2]. Group 2: Legal Context - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of fighting for the rights of victims of securities fraud and corporate misconduct [3].

Core Viewpoint - The article discusses a securities investigation concerning XBiotech Inc. (XBIT) and encourages stockholders to inquire about the matter [1] Group 1 - The law firm Bronstein, Gewirtz & Grossman, LLC is urging XBiotech Inc. stockholders to seek information regarding a potential investigation into the company's securities [1] - The investigation may relate to possible violations of securities laws, which could impact the stockholders' interests [1] - Stockholders are encouraged to contact the law firm for further details and to understand their rights [1]

Core Viewpoint - XBiotech Inc. is under investigation for potential violations of securities laws, prompting affected investors to reach out to the Schall Law Firm for assistance [1] Group 1 - The investigation into XBiotech Inc. suggests serious legal concerns that may impact the company's reputation and financial standing [1] - Affected investors are encouraged to take action by contacting legal representation, indicating potential for class action or legal claims [1]

Core Viewpoint - Bronstein, Gewirtz & Grossman LLC has announced an investigation into XBiotech Inc. to determine whether the company has violated securities laws, encouraging investors to reach out for more information [1] Group 1 - The investigation is focused on potential violations of securities laws by XBiotech Inc. [1] - Investors are being encouraged to contact the firm for further details regarding the investigation [1]

Core Viewpoint - The Schall Law Firm is inviting shareholders of XBiotech Inc. who have experienced losses to participate in an inquiry regarding potential securities fraud involving the company [1] Group 1 - The inquiry is focused on allegations of securities fraud that may have impacted shareholders negatively [1] - Shareholders are encouraged to join the inquiry to explore their legal options and potential recovery of losses [1] - The law firm is actively seeking to gather information and evidence related to the alleged fraud [1]

Core Viewpoint - Bronstein, Gewirtz & Grossman, LLC is encouraging investors of XBiotech Inc. (XBIT) to inquire about a securities investigation related to the company [1] Group 1 - The investigation may involve potential securities violations by XBiotech Inc. [1] - Investors are urged to seek more information regarding their rights and potential claims [1] - The firm specializes in securities class action lawsuits and is actively pursuing this matter [1]